Restarting the trial will require the company to raise additional funds before its money runs out this summer.

The project stems from a microRNA drug and diagnostics partnership forged earlier this year.

The higher losses came amid increased costs.

Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatorial Cloning
Patent Number: 8,877,435

NEW YORK (GenomeWeb) – Marina Biotech this week took another step toward reestablishing itself as a player in the nucleic acids drug sector, regaining compliance with US Securities and Exchange Commission financial reporting requirements with the submission of the requisite information for 2012,

Marina Biotech announced that it has appointed Daniel Geffken as its interim CFO as it works to restart drug-development operations after halting operations in mid-2012 amid a cash shortfall. Geffken is managing director at Danforth Advisors.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Rosetta Genomics and RNA drug developer Marina Biotech today announced that they have forged a microRNA diagnostics and drug discovery and development alliance, focusing on neuromuscular diseases and dystrophies.

Having just closed its first financing transaction in two years, struggling Marina Biotech announced that it plans to continue looking beyond just RNAi and develop drugs using a number of different nucleic acid modalities.

Amid a resurgence of investor interest in RNAi as a therapeutic modality, two of the field's smaller players this week announced financing arrangements expected to help them reach key inflection points — news that prompted double-digit jumps in each company's share price.

Art Krieg has been named as CSO of RNA drug developer Sarepta Therapeutics.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.